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ARTICLE OPEN
Mimicking immune signatures of ﬂavivirus infection with
targeted adjuvants improves dengue subunit vaccine
immunogenicity
Katell Bidet1, Victor Ho2,3, Collins Wenhan Chu4, Ahmad Nazri Hohamed Naim4, Khaing Thazin5, Kuan Rong Chan 6,
Jenny G. H. Low 6,7, Milly M. Choy4, Lan Hiong Wong1, Paola Florez de Sessions4, Yie Hou Lee 8, Martin L. Hibberd9, Eng Eong Ooi1,6,
Katja Fink 2,3 and Jianzhu Chen1,10
Neutralizing antibodies (nAbs) are a critical component for protection against dengue virus (DENV) infection, but little is known
about the immune mechanisms governing their induction and whether such mechanisms can be harnessed for vaccine
development. In this study, we proﬁled the early immune responses to ﬂaviviruses in human peripheral blood mononuclear cells
and screened a panel of toll-like receptor (TLR) agonists that stimulate the same immune signatures. Monocyte/macrophage-driven
inﬂammatory responses and interferon responses were characteristics of ﬂavivirus infection and associated with induction of nAbs
in humans immunized with the yellow fever vaccine YF-17D. The signatures were best reproduced by the combination of TLR
agonists Pam3CSK4 and PolyI:C (PP). Immunization of both mice and macaques with a poorly immunogenic recombinant DENV-2
envelope domain III (EDIII) induced more consistent nAb and CD4+ T-cell responses with PP compared to alum plus
monophosphoryl lipid A. Induction of nAbs by PP required interferon-mediated signals in macrophages in mice. However, EDIII+
PP vaccination only provided partial protection against viral challenge. These results provide insights into mechanisms underlying
nAb induction and a basis for further improving antigen/adjuvant combinations for dengue vaccine development.
npj Vaccines            (2019) 4:27 ; https://doi.org/10.1038/s41541-019-0119-3
INTRODUCTION
The dengue viruses (DENV) are single-stranded RNA viruses of the
ﬂavivirus family and are divided into four serotypes (DENV-1-4).1
DENV infection is initiated by bite of an infected mosquito. In the
skin, Langerhans cells, conventional dendritic cells (DCs), macro-
phages (Mφs) and keratinocytes are believed to be the primary
targets of infection, which can then spread to other organs
through draining lymph nodes.2–4 In most individuals, DENV
infection induces virus-speciﬁc Abs and CD4+ and CD8+ T cells,
which provide protection against subsequent infection by the
same serotype but only temporary cross-protection against
different serotypes of DENV.1,4
Neutralizing antibodies (nAbs), which bind to viral structures
and prevent virus infection by blocking virus binding to and/or
fusion with the host cells,5–7 are a critical component in the
protection against DENV. Epidemiological studies have shown that
high titers of pre-existing nAb (up to >1:300) are associated with
lower disease incidence.8–10 nAbs are also required for protection
conferred by the most effective ﬂavivirus vaccine developed to
date, the yellow fever vaccine YF-17D.11 Systems biology studies
of the YF-17D infection in human subjects have shown that nAb
responses are associated with the activation of type I interferon
(IFN) responses and could be predicted by the induction of
individual transcripts such as the B-cell growth factor receptor
TNFRSF17.12–14 On the other hand, B-cell and plasmablast (PB)
responses were negatively correlated with YF-17D-induced nAb
responses in the same cohorts.13 Ab responses to DENV are
characterized by a dramatic increase in circulating Ab-producing
cells or PBs resulting in high titers of DENV-reactive Abs.15,16
However, this is not correlated with nAb responses,17,18 suggest-
ing that generation and/or selection of nAbs might require
immune events different from those mediating the development
of high titers of reactive Abs. Despite their importance in dengue
vaccine development, the immune mechanisms underlying nAb
response to DENV infection are largely unknown.
Induction of strong nAb responses has been at the center of the
quest to develop effective dengue vaccines. The only DENV
vaccine approved to date, a tetravalent chimeric live attenuated
virus (LAV), induces imbalanced and poorly protective responses
in DENV-naïve subjects.19,20 Subunit vaccines based on recombi-
nant proteins could potentially improve the quality of immune
responses, as they offer the possibility to control the epitopes and
amount of antigen delivered and to ﬁne-tune the type of immune
responses induced using adjuvants. The use of the envelope
protein domain III (EDIII), which is the target of highly neutralizing
and protective serotype-speciﬁc Abs, was investigated as a
Received: 8 March 2018 Accepted: 3 June 2019
1Interdisciplinary Research Group in Infectious Diseases, Singapore-MIT Alliance for Research and Technology, Singapore, Singapore; 2Singapore Immunology Network, Agency
for Science, Technology and Research, Singapore, Singapore; 3School of Biological Sciences, Nanyang Technological University, Singapore, Singapore; 4Genome Institute of
Singapore, Agency for Science, Technology and Research, Singapore, Singapore; 5Department of Biological Sciences, National University of Singapore, Singapore, Singapore;
6Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore, Singapore; 7Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore;
8KK Women’s and Children’s Hospital, Singapore, Singapore; 9Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT,
UK and 10Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Correspondence: Jianzhu Chen (jchen@mit.edu)
www.nature.com/npjvaccines
Published in partnership with the Sealy Center for Vaccine Development
possible way to circumvent immune interference between
serotypes. However, immunogenicity of EDIII was poor and
required an extensive immunization schedule and high doses in
order to elicit nAb responses.20 Therefore, new strategies targeted
speciﬁcally at increasing nAb responses are needed.
It has become increasingly clear that different vaccines rely on
the activation of speciﬁc immune programs that determine
immunogenicity.12,13,21 Differences in the activation of innate
immune receptors—including toll-like receptors (TLR)—after a
natural infection can tailor the generation of adaptive immune
responses speciﬁc to the pathogen.22,23 These differences could
be harnessed for vaccine development, where the use of speciﬁc
combinations of TLR agonists led to optimization of responses
against several pathogens.24–26
In this study, we sought to identify immune signatures
associated with induction of high nAb responses to DENV in
humans and mimic these mechanisms with targeted adjuvants to
enhance nAb responses to a model DENV subunit vaccine. We
applied a systems biology approach to identify the immune
signatures following infection of human PBMCs with a panel of
clinically well-characterized ﬂaviviruses. We showed that IFN
responses and proinﬂammatory responses driven by monocytes/
Mφs are consistently associated with infection by immunogenic
ﬂaviviruses. We reproduced these signatures using a selected
combination of two TLR agonists. Immunization of both mice and
macaques with the recombinant EDIII in the presence of the
adjuvant combination induced more consistent nAb and T-cell
responses, as well as partial protection against virus challenge. Our
study identiﬁes the early immune signatures associated with nAb
responses to DENV and adjuvant combinations that mimic such
immune signatures to promote more consistent immune
responses to DENV subunit vaccine among recipients.
RESULTS
Flaviviruses and adjuvants induce PBMC responses in vitro
To investigate which adjuvants could mimic features of immuno-
genic virus infections, we used human peripheral blood mono-
nuclear cells (PBMCs) as a model system. We validated the system
by comparing the transcriptional changes in four healthy donor
PBMCs following YF-17D infection in vitro to the changes in whole
blood of four volunteers after YF-17D vaccination (Supplementary
Fig. 1). Consistent with previous reports, IFN signatures dominated
both the in vivo and in vitro responses to infection. In total 94 out
of 173 differentially expressed transcripts and 9 out of 10 top
upstream regulators identiﬁed by ingenuity pathway analysis (IPA)
changed by in vivo infection were similarly changed after in vitro
infection. As observed in vaccinees,12 YF-17D infection of PBMCs
also induced upregulation of activation markers on various
immune cells, including CD80 and CD86 on myeloid DCs (mDCs)
and CD54 and CD69 on monocytes (Fig. 1a and Supplementary
Fig. 2). These results suggest that the PBMC model system could
be a useful alternative to in vivo experiments to study the
signatures of early response to ﬂaviviruses.
To identify immune signatures induced by viral infection we
compared a panel of ﬁve well-characterized ﬂaviviruses in the
PBMC model system. Four viruses were from dengue vaccine
development efforts at Mahidol University: the LAVs DENV-2
PDK53 and DENV-3 PGMK30FhL3 and their parent viruses DENV-2
16681 and DENV-3 16562, isolated from dengue hemorrhagic
fever patients. In tetravalent formulations in clinical trials, DENV-3
PGMK30FhL3 was consistently more immunogenic than DENV-2
PDK53 in inducing both seroconversion and T-cell responses.27–30
The ﬁfth virus was the LAV YF-17D, a benchmark for a safe
ﬂavivirus vaccine with reliable induction of high nAb titers and
CD8 T-cell responses in most vaccinees.12 PBMCs from four
healthy, dengue-naïve donors were infected with the viruses and
expression of activation markers on mDCs, plasmacytoid DCs,
monocytes, NK, T, and B cells was analyzed (Supplementary Fig. 2);
cytokines in the culture supernatants were quantiﬁed; and the
transcriptomic proﬁle of the infected cells was analyzed by
microarray after 48 h.
To delineate which immune signatures contribute to strong B-
cell and T-cell responses rather than to virus pathogenicity or
changes in cell metabolism, we applied the following criteria:
signatures of interest should be (1) consistently upregulated or
downregulated across several viruses, (2) shared by LAV and WT
viruses, and (3) strongly activated after infection by YF-17D. All WT
and LAVs induced the upregulation of activation markers CD80
and CD86 on BDCA-1+ mDC (mDC-1) and monocytes, but not
consistently on other cell types (Fig. 1a). DENV-3 16562 and YF-
17D were the only two viruses that induced a signiﬁcant
upregulation of the activation markers CD69 and CD25 on CD4,
CD8 T cells and B cells. Although there was more variability in the
levels of cytokines induced by the different viruses in different
donors, we could detect signiﬁcant upregulation of CCL3/MIP-1α,
CCL4/MIP-1β, IL-6, and CXCL10/IP-10 by two or more viruses (Fig.
1b), consistent with previous reports.12,31,32 Transcription of
hundreds of genes was signiﬁcantly altered after infection.
DENV-2 16681, DENV-3 16562, and YF-17D induced the most
numbers of changes (Supplementary Fig. 3a). Based on IPA
analysis, only DENV-2 16681, DENV-3 16562, and YF-17D induced
activation of pathways related to innate immune responses
(Supplementary Fig. 3b). Among the pathways most strongly
activated (with the highest Z-score) by YF-17D were IFN signaling,
IL-1 signaling, TLR signaling, and acute phase response signaling.
DC maturation appeared as an important component of the
cellular responses to infection that was shared by all viruses (Fig.
1c). This was consistent with the transcriptional activity of
proinﬂammatory cytokines TNF and IFNs (IFN-α, IFN-γ, and IFN-λ)
as upstream regulators (Fig. 1d).
In parallel, we assayed the responses of the same four donor
PBMCs to a panel of TLR agonists: TLR1/2 agonist Pam3CSK4
(triacylated lipopeptide), TLR3 agonist PolyI:C (synthetic double-
stranded RNA), TLR4 agonist LPS (bacterial lipopolysaccharide),
TLR7/8 agonist R848 (nucleoside analog), and TLR9 agonist
ODN2006 (CpG oligonucleotide). Aluminum hydroxide (alum), a
traditional adjuvant used in many commercial vaccines, served as
a non-TLR agonist control. Compared to alum, which did not
activate any immune cells, the TLR agonists activated many cell
types and all ﬁve agonists activated mDC-1 (Supplementary Fig.
4a). All stimuli signiﬁcantly induced IL-6 and IL-1β secretion
(Supplementary Fig. 4b). Pam3CSK4, LPS, and R848 also stimulated
secretion of CCL3/MIP-1α, CCL4/MIP-1β, and IFN-γ. Based on the
transcriptomic proﬁle, alum induced signatures of translational
downregulation similar to DENV-2 PDK53 (Supplementary Figs. 4c
and 3b). In contrast, the TLR agonists induced strong immunolo-
gical signatures involving immune cell trafﬁcking, IFNs, and
proinﬂammatory and T-cell responses.
In summary, although most features induced by viral infections
were also induced by adjuvants, no single TLR agonist fully
reproduced the viral signatures.
Gene modules linking monocyte/Mφ, pro-inﬂammatory responses,
and Th1 cytokines are associated with ﬂavivirus infection
To gain better insight into the potential links between the
signatures identiﬁed, we performed an integrated analysis of the
phenotypic, cytokine, and transcriptomic proﬁles using weighted
correlation network analysis (WGCNA).33 The 48 microarray
datasets from four donor PBMCs treated with viruses or adjuvants
were used to construct a correlation network and identify gene
modules with shared expression patterns, which were color-coded
(Fig. 2a). We examined the average fold change expression of all
genes in each module after treatment with viruses and TLR
K. Bidet et al.
2
npj Vaccines (2019)    27 Published in partnership with the Sealy Center for Vaccine Development
1
2
3
4
5
6
7
8
9
0
()
:,;
agonists (Fig. 2b). Module green–yellow showed the strongest
activation by viruses, with an average fold change of gene
expression >2 for all ﬁve viruses tested. Modules purple and cyan
were also consistently induced. Importantly, these modules were
not associated with pathogenicity as they were induced by both
WT and LAV.
Expression of each module was related to external traits
(activation of individual immune cell subsets and cytokine
expression) and pathways analyzed using IPA and gene set
enrichment analysis (GSEA)34 (summary in Fig. 2c–e, full table in
Supplementary Fig. 5). Module green–yellow was strongly
correlated with CD4 T-cell and B-cell activation, as well as with
levels of the cytokines IFN-α, IL-2, and CXCL10/IP-10 (Fig. 2c).
Transcripts in module green–yellow were categorized into IFN-α-
induced and IFN-γ-induced genes under the control of STAT and
IRF transcription factors in both GSEA and IPA analysis (Fig. 2d and
Supplementary Fig. 6a–c). Module purple was associated with B-
cell activation and levels of proinﬂammatory cytokines IL-6, IL-1β,
TNF-α, and CCL3/4/5/11, as well as classical Th1 cytokines IL-12
and IFN-γ (Fig. 2c and Supplementary Fig. 5). Analysis of module
purple transcripts revealed a signiﬁcant enrichment in GSEA
hallmark pathways such as TNF-α signaling through NF-κB and
inﬂammatory responses (Fig. 2d), which were conﬁrmed by IPA
analysis (Supplementary Fig. 6d–f). Signatures in module cyan
appeared to overlap with those of module green–yellow, with a
strong component of IFN responses, even though it exhibited a
unique negative correlation with NK-cell activation and expression
of IL-17 and EGF (Fig. 2c–e). Module tan was also strongly
associated with B-cell activation and levels of IFNs (Fig. 2c and
Supplementary Fig. 5). However, at the transcript level, this
module was not enriched in immune genes but mainly in genes
involved in cell growth and metabolism (Fig. 2d). While modules
green–yellow and purple were strongly induced after both virus
and adjuvant treatments, module tan was upregulated by R848
and ODN2006 but not ﬂavivirus infection (Fig. 2b), suggesting that
distinct immune mechanisms might be involved in shaping B-cell
activation.
Fig. 1 Immune signatures of PBMC responses to ﬂavivirus infection. PBMCs from four healthy donors were infected with the different viruses
at MOI= 1 and analyzed after 48 h for immune cell activation, cytokine secretion, and transcriptomic response. a MFI of activation markers on
immune cell subtypes. Antibodies against the two activation markers were labeled with the same ﬂuorophore. b Cytokine concentrations in
the supernatant, in pg/ml. Data shown are box plots depicting the median, 25th and 75th percentiles with whiskers showing the min to max
distribution of four independent donors. Signiﬁcant differences are determined using a two-tailed paired t test between infected and mock
condition for each donor. *p < 0.05, **p < 0.01, ***p < 0.005. c, d Heatmap of Z-score of pathways upregulated after infection (c) and upstream
regulators (d) analyzed by ingenuity pathway analysis
K. Bidet et al.
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One important observation from this analysis was that the
inﬂammatory module purple triggered by ﬂavivirus infection
appeared to be mainly associated with monocytic cells, whereas
other modules, such as IFN-related responses, were not assigned
to a speciﬁc cell type when assessing the overlap with GSEA
Immunological Genesets (Fig. 2e). To test this hypothesis
experimentally, we generated human monocyte-derived DCs
(MDDCs) and macrophages (MDMΦs), infected them with DENV-
2 16881 and assayed after 48 h for induction of representative
gene associated with NF-κB driven proinﬂammatory (CCL3/MIP-
1α) and IFN signaling (IFIT1). While there was no difference in
levels of IFIT1 between MDDCs and MDMΦs, CCL3/MIP-1α was
upregulated at signiﬁcantly higher levels in MDMΦs (Fig. 2f–h).
Thus, MΦs are likely the major cell type producing the
proinﬂammatory cytokine CCL3/MIP-1α while IFN responses are
induced across DENV-infected cells.
K. Bidet et al.
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Speciﬁc immune signatures are associated with YF-17D
immunogenicity
To evaluate which of these signatures could be associated with
strong nAb responses after vaccination in humans, we used
clinical data from a cohort of 11 ﬂavivirus-naïve individuals
immunized with YF-17D.21 PRNT50 titers in all individuals at one-
month post vaccination, serum cytokine levels in all individuals at
days 3 and 7 post vaccination, and whole blood microarray data
for 7 of these 11 individuals at 3 days post vaccination were
analyzed. Because the sample size was too small to apply WGCNA,
we selected the top three responders versus bottom three
responders (Fig. 3a) and performed GSEA analysis of the
transcriptomic data to identify pathways differentially regulated
between the two groups. Although innate immune signatures
were induced in all individuals, consistent with our proinﬂamma-
tory module predictions, the top responders showed signiﬁcant
enrichment of pathways associated with NF-κB signaling,
inﬂammatory, and IFN-γ responses and monocyte gene signatures
compared to the bottom responders (Fig. 3b, c). In contrast, the
bottom responders showed enrichment of pathways linked to
stress responses and cell proliferation with a strong B-cell
component. PRNT50 was not correlated with viral load in this
cohort (Supplementary Fig. 7a, b), suggesting that although high
viral replication drives potent immune responses, it is not
sufﬁcient to explain the individual variations in nAb responses.
We also examined the levels of serum cytokines at 7 days post
vaccination. Levels of IL-12, IFN-γ, TNF-α, CCL11/Eotaxin (asso-
ciated with module purple in WGCNA), and IFN-α and IL-2
(associated with module green–yellow in WGCNA) were found to
correlate with PRNT50 titers in the vaccinees (Fig. 3d and full table
in Supplementary Fig. 7c). All these cytokines are generally linked
to Th1 responses. None of the cytokines associated with other
WGCNA modules correlated with nAb responses. Therefore, the
gene signatures identiﬁed in the PBMC model can be largely
validated following YF-17D vaccination in humans. Nonetheless,
Fig. 2 WGCNA analysis of gene modules induced by ﬂavivirus infection identiﬁes potential cell-speciﬁc signatures. a–e Gene expression data
from all PBMCs infected with ﬂaviviruses or treated with TLR agonists were used in WGCNA to identify gene modules induced by ﬂavivirus
infection. a Clustering dendrogram of genes with dissimilarity based on topological overlap used for module detection. Height represents the
level of coexpression and color blocks indicate the gene modules identiﬁed. b Heatmap of module induction after ﬂavivirus infection and TLR
agonist treatment. Module induction was calculated as the average log2 expression of all genes in the module for all four donors after
treatment normalized to the average log2 expression of all genes in the module for all four donors in mock-treated PBMCs. c Correlation of
selected module expression with cytokine and cell activation. Data are shown here for modules tan, cyan, purple, and green–yellow. The full
WGCNA correlation table is shown in Supplementary Fig. 5. d, e GSEA analysis of enriched hallmark genesets (d) and immunological genesets
(e) in modules tan, cyan, purple, and green–yellow. f–h Cell-speciﬁc upregulation of CCL3/MIP-1α and IFIT1 transcripts after DENV-2 infection
in monocyte-derived DCs (MDDCs) and macrophages (MDMΦs). f Experimental scheme. MDDCs and MDMΦs were generated from
monocytes isolated from PBMCs of healthy human donors by culturing for 8 days in the presence in GM-CSF and IL-4 or M-CSF, respectively.
g Conﬁrmation of expression of CD11c, CD209/DC-SIGN, and HLA-DR on MDDCs and CD14 and CD68 and HLA-DR on MDMΦs immediately
before infection. h Relative levels of DENV-2 RNA, IFIT1, and CCL3/MIP-1α transcripts at 48-h post infection with DENV-2 16681 at MOI= 1
measured by quantitative real-time RT-PCR and normalized to GAPDH. Data shown are the mean ± SEM of three independent donors.
Signiﬁcant differences are calculated using a two-tailed paired t test between MDDCs and MDMΦs. *p < 0.05, ***p < 0.005
Fig. 3 Signatures associated with nAb responses in YF-17D vaccinees. a nAb titers from the top three and bottom three responders for which
microarray data were available in the cohort. Signiﬁcant differences are determined using a two-tailed paired t test. *p < 0.05. b, c Top ﬁve
pathways signiﬁcantly enriched in comparing the transcriptomic signatures at 3 days post-YF-17D vaccination for three high responders and
three low responders using GSEA Hallmark database (b) and GSEA Immunologic signature database (c). d Correlation plots between the log2
concentration of cytokines in the serum at 7 days post vaccination and the PRNT50 titer against YF-17D at 1-month post vaccination. One dot
represents one individual. The three high responders and three low responders used in the GSEA analysis are highlighted in red and blue,
respectively. The black dots represent the remaining individuals in the cohort whose responses were in between. A list of all cytokines
analyzed is shown in Supplementary Fig. 7c. e Proposed model of immune signatures leading to high nAb responses to ﬂavivirus infection
K. Bidet et al.
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since other major cytokines associated with module purple such
as IL-6, IL-10, and CCL5/RANTES did not correlate with the nAb
response in vaccinees, it is possible that proinﬂammatory
responses are involved indirectly through activation of T-cell
responses.
In summary, the following early immune signatures after
infection are associated with the generation of nAb responses in
naïve individuals (Fig. 3e): (1) activation and maturation of mDCs,
(2) a proinﬂammatory response driven by NF-κB transcription in
monocyte/MΦs, (3) IFN signaling in multiple cell types, and (4) a
Th1 cytokine environment.
A combination of TLR1/2 and TLR3 agonists induces similar
immune signatures as ﬂavivirus
Next, we determined which TLR agonists could induce similar
immune signatures in PBMCs based on the data in Supplementary
Fig. 4. At the tested dose, Pam3CSK4 induced the strongest
upregulation of activation markers on both mDC-1 and monocytes
(Fig. 4a). PolyI:C potently activated the speciﬁc signatures of DC
maturation, IFN-α and IFN-γ signaling, as well as IL-2 and CXCL10/
IP-10 cytokines. Pam3CSK4, LPS, and R848 induced cytokines
associated with the proinﬂammatory module. However, secretion
of several of these cytokines in response to LPS and R848 was
orders of magnitude higher than after YF-17D infection. In
addition, R848 was linked in the WGCNA analysis to induction of
modules tan, yellow, and magenta, which were not induced by
ﬂavivirus infection (Fig. 2b). Therefore, we selected the combina-
tion of Pam3CSK4 and PolyI:C (thereafter referred to as PP) as best
reproducing the signatures of ﬂavivirus infection.
We directly tested the PP combination in the PBMCs from four
additional unrelated donors (Fig. 4b–g). PP induced similar or
better responses than its individual adjuvants for all tested
parameters: upregulation of CD80 and CD86 on mDC-1, CD54 and
CD86 on monocytes (Fig. 4b, c), induction of Th1 cytokines IL-12
and IFN-γ (Fig. 4d, e), and upregulation of IFN-induced transcripts
IFIT1 and OAS2 (Fig. 4f, g). We also tested the combination using
NF-κB and IFN-stimulated response element (ISRE) reporters in
monocytic THP-1 and T lymphocytic Jurkat cell lines (Fig. 4h). PP
induced a strong NF-κB response in monocytes and ISRE response
in both cell types (Fig. 4i, j). This conﬁrms that the expected
signatures were induced by PP.
The PP adjuvant combination induces nAb responses in mice
We determined whether the PP adjuvant combination could
improve the immune response to vaccination using recombinant
DENV-2 EDIII as a model dengue subunit vaccine. C57BL/6 mice
were immunized subcutaneously twice at 14-day interval with a
low dose of 5 µg of EDIII adjuvanted with PP or with alum plus
MPLA (referred to as AL), a standard combination used in several
commercialized vaccines (Fig. 5a).25 As control, C57BL/6 mice were
infected subcutaneously with DENV-2 16681. Compared to AL, PP
induced stronger activation of CD11b+ DCs (equivalent to mDC-1
in human), Ly6C+ monocytes (equivalent to classical human
monocytes), and IFN-induced IFIT1 in the blood 1 day after
vaccination (Supplementary Fig. 8).
The antibody response was quantiﬁed 14 days after the boost.
When total EDIII-speciﬁc IgG was measured by ELISA, EDIII without
adjuvant did not induce any signiﬁcant response. The addition of
Fig. 4 A combination of Pam3CSK4 and PolyI:C (PP) recapitulates signatures of high nAb responses. a Heatmap showing cell activation,
cytokines, and pathway signatures associated with nAb responses induced in human PBMCs by alum and TLR agonists. The data were
selected from the experiment presented in Supplementary Fig. 5 and compared to the same changes triggered by YF-17D in the same donor
PBMCs, presented in Fig. 1. b–g Immune stimulation by individual and combination of Pam3CSK4 and PolyI:C in human PBMCs. b, c MFI of
activation markers on mDC-1 and monocytes. Antibodies against activation markers were labeled with the same ﬂuorophore. d, e Levels of IL-
12 and IFN-γ in the supernatant. f, g Induction of IFN-stimulated IFIT1 and OAS2 mRNA by quantitative real-time RT-PCR, normalized to
GAPDH. h–j Activation of reporter genes in reporter cell lines. h Schematic reporter constructs in THP-1 and Jurkat cell lines. i, j Induction of
NF-κB and ISRE reporter in THP1 and Jurkat cells. Data shown are the mean ± SEM for four independent PBMC donors or two independent
experiments in triplicate for cell lines. Signiﬁcant differences are determined using a two-tailed paired t test between treatment and mock.
*p < 0.05, **p < 0.01, ***p < 0.005
K. Bidet et al.
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AL or PP both increased IgG titers, although the response to AL
was two orders higher than PP (Fig. 5b). DENV-2 also induced a
high level of antigen-speciﬁc IgG response. In contrast, when nAbs
were measured by PRNT, addition of PP induced higher PRNT50
titers than AL, reaching levels similar to those induced by
immunization with DENV-2 (Fig. 5c). The addition of AL induced
predominantly an IgG1 response to EDIII, whereas the addition of
PP also induced signiﬁcant proportions of IgM and IgG2b leading
to an isotype proﬁle more similar to the response to DENV-2
(Fig. 5d). We analyzed germinal center (GC) and IgG+ PB formation
Fig. 5 The PP adjuvant combination induces high nAb responses in mice, dependent on the presence of functional macrophages. a–f C57BL/
6 mice were immunized twice at 14-day interval with DENV-2, EDIII alone or combined with AL or PP, and immune response analyzed as
shown in a. b Log10 EDIII-speciﬁc IgG titers, (c) log10 PRNT50 titers, and (d) proportion of EDIII-speciﬁc IgM, IgG1, IgG2b, IgG2c, and IgG3 in the
serum of the indicated mice at 28 days post vaccination (n= 9−10 mice per group from two independent experiments). Isotyping was done
on pooled samples for each group. e, f Seven days post initial immunization, spleens were harvested from two mice per group and GCs
detected by IFA. Representative images are shown in Supplementary Fig. 9. e Quantiﬁcation of GCs in the entire spleen section for two mice
per group. f Quantiﬁcation of IgG+ cells (PBs) in two 1mm2 areas for each spleen section. Data shown are the mean ± SEM. g–h C57BL/6 mice
were treated with PBS-L or CL-L before immunization with EDIII+ PP as shown in g. Cell depletion after CL-L treatment is shown in
Supplementary Fig. 10. h Log10 PRNT50 titers at 28 days post vaccination (n= 9–10 mice per group from two independent experiments). i, j
Conditional IFNAR knockout mice CD11c-Cre IFNARﬂ/ﬂ and LysM-Cre IFNARﬂ/ﬂ were immunized with EDIII+ AL or EDIII+ PP as shown in i.
Viremia was analyzed by plaque assay in the serum 4 days after DENV-2 challenge in CD11c-Cre IFNARﬂ/ﬂ (i) and in LysM-Cre IFNARﬂ/ﬂ mice (j)
(n= 8–10 mice per group from two independent experiments). Data shown are the mean ± SEM. Signiﬁcant differences are determined by
unpaired two-tailed t test. ns, not signiﬁcant, *p < 0.05, **p < 0.01, ***p < 0.005
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in the spleen 7 days after the ﬁrst immunization. DENV-2, EDIII+
AL, and EDIII+ PP induced comparable numbers of GCs, although
the GCs were smaller in size in mice immunized with EDIII+ PP
(Fig. 5e and Supplementary Fig. 9). However, EDIII+ AL induced
more IgG+ PBs compared to EDIII+ PP or DENV-2 immunization
(Fig. 5f). These results suggest that PP induces a superior nAb
responses to EDIII than AL, reaching a similar nAb level as induced
by virus infection.
To investigate the requirement of MΦs in nAb responses to PP,
we used clodronate liposomes (CL-L) to deplete MΦs in C57BL/6
mice prior to immunization (Fig. 5g).35 Injection of CL-L before
EDIII+ PP, and then again before the boost, speciﬁcally reduced
the numbers of F4/80+ and CD169+ MΦs without affecting
CD11c+ DCs or CD19+ B cells in the spleen (Supplementary
Fig. 10). Resulting nAb titers were approximately tenfold lower in
CL-L-treated mice than mice treated with control PBS-L (Fig. 5h),
indicating that MΦs are required for generating nAb responses to
EDIII+ PP vaccination.
We further examined the requirement for MΦ-speciﬁc innate
immune signaling for the induction of protective responses in a
challenge model. We used the recently described CD11c-Cre+/−
IFNARﬂ/ﬂ and LysM-Cre+/− IFNARﬂ/ﬂ mice, which lack IFN-α
receptor exclusively in CD11c+ DCs and LysM+ MΦs, respectively.
These mice support productive DENV-2 infection and remain
capable of mounting antibody and T-cell responses to subunit
vaccines.36 Both strains of mice were immunized subcutaneously
at days 0 and 14 with EDIII+ AL or EDIII+ PP (5 μg EDIII per dose)
and challenged intraperitoneally on day 28 with DENV-2 D2Y98P
(106 PFUs). Viremia was analyzed 4 days later (Fig. 5i). In CD11c-
Cre+/− IFNARﬂ/ﬂ mice, immunization with EDIII+ AL did not
signiﬁcantly reduce DENV-2 viremia compared to unvaccinated
controls, whereas EDIII+ PP did confer a signiﬁcant, albeit partial,
protection against DENV-2 challenge (Fig. 5j). In LysM-Cre+/−
IFNARﬂ/ﬂ mice, immunization with EDIII+ AL or EDIII+ PP did not
reduce DENV-2 viremia when compared to unvaccinated mice
(Fig. 5k), indicating that IFN responses in MΦs are required for nAb
responses. Taken together, the results from different mouse
models show the superiority of PP as adjuvant in inducing nAb
response and the requirement for MΦ in responses to EDIII+ PP
vaccination.
PP elicits more consistent nAb and T-cell responses in nonhuman
primates (NHPs), but only confers partial protection against virus
challenge
Next we vaccinated and challenged cynomolgus macaques. Ten
DENV-2-naïve animals were divided into three groups: two were
given PBS (control), four were immunized subcutaneously with
EDIII+ AL, and four with EDIII+ PP twice at 28-day interval
(Fig. 6a). Because PolyI:C is not stable in the circulation of NHPs
and humans, PolyICLC was used in the PP formulation.37 Both
vaccines were well tolerated, with no clinical manifestations more
severe than a mild reaction at injection site, no fever, and no
elevation in alanine transferase (ALT) levels between days 1 and 7
post vaccination (Supplementary Fig. 11a, b). Levels of serum
proinﬂammatory cytokines CCL2/MCP-1 and CXCL10/IP-10, induc-
tion of IFIT1 in the blood and expression of CD80 and CD86 by
mDCs were signiﬁcantly higher in EDIII+ PP compared to EDIII+
AL immunized NHPs at day 1 post vaccination (Supplementary Fig.
11c–f). However, serum levels of Th1 cytokines IFN-γ and TNF-α
were only upregulated in two of four EDIII+ PP immunized NHP,
and no upregulation of activation marker CD86 was detected on
blood monocytes after vaccination (Supplementary Fig. 11g–i).
These results indicate that, at the dose used, PP induced some but
not all expected immune signatures in NHPs. We also noted that
Fig. 6 The PP adjuvant combination elicits more consistent nAb and T-cell responses in NHPs. a Immunization and challenge scheme in
cynomolgus macaques. b Responses of individual NHPs to vaccination and challenge. Columns 1–4: animal identiﬁcation number, sex (M/F),
and body weight. Columns 5–7: reciprocal DENV-2 PRNT50 titer in the serum at day 1 (pre vaccination), day 28 (pre boost), and day 56 (pre
challenge). PRNT50 below detection value are noted as 5. Columns 8 and 9: frequency of EDIII-speciﬁc IFN-γ responsive CD4+ and CD8+ T cells
in the spleen at day 63. Columns 10 and11: Viremia, deﬁned as the area under the curve (AUC) of DENV-2 titers in the serum of challenged
animals between days 56 and 53 (days 1–7 post challenge) measured by qRT-PCR and plaque assay. c Log10 DENV-2 PRNT50 titer by group at
day 56 post vaccination. d, e Frequency of EDIII-speciﬁc IFN-γ responsive CD4+ (d) and CD8+ (e) T cell by group at day 63. Data shown are box
plots depicting the median, 25th and 75th percentiles with whiskers showing the min to max distribution for each group. Signiﬁcant
differences are determined by unpaired two-tailed t test. ns: not signiﬁcant, *p < 0.05
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one animal (6303) in the EDIII+ AL group showed high levels of
serum IFN-γ and TNF-α before and throughout day 7 post
immunization (Supplementary Fig. 11g, h), indicating a speciﬁc
immune status potentially due to an unrelated concomitant
infection.
EDIII-speciﬁc IgG was analyzed by ELISA and nAb titers by PRNT
over time. After priming, the AL formulation induced signiﬁcantly
higher IgG titers than PP; however, unlike in mice there was no
difference between the two groups after the boost (Supplemen-
tary Fig. 12a, b). Nonetheless, as in mice the ratio of EDIII-speciﬁc
IgG1 versus total IgG was higher in the AL than PP vaccinated
NHPs (Supplementary Fig. 12c). One month after the boost, two
animals vaccinated with EDIII+ AL had high nAb titers, while the
other two did not have detectable nAbs (Fig. 6b). In the EDIII+ PP
immunized group, all animals developed nAb titers. Overall, only
the EDIII+ PP group had a signiﬁcant nAb response after two
immunizations (Fig. 6c). In all vaccinated animals, nAb titers did
not correlate to the total IgG or IgG1 titers (Supplementary Fig.
12d, e).
At day 56, NHPs were challenged subcutaneously with 106 PFUs
of DENV-2 16681. Viremia was measured by plaque assay and viral
RNA quantiﬁed by real-time PCR in the serum daily for 7 days. In
the control animals, both viremia and viral RNA were detected for
6 or 7 days following challenge (Fig. 6b and Supplementary
Table 1). Both EDIII+ PP and EDII+ AL vaccinated animals had a
reduced level of viremia, indicating partial protection against virus
challenge; however, PP did not perform better than AL. The only
animal that was completely protected (no virus detected by either
method) was from the EDIII+ AL group (6303). This was the
animal with the highest nAb titers but also high baseline levels of
Th1 cytokines. Thus, the speciﬁc immune status of this animal
might have inﬂuenced nAb responses and protection indepen-
dently of the EDIII+ AL vaccination.
To assay EDIII-speciﬁc T-cell response, splenocytes were
analyzed at 7 days post challenge for IFN-γ and TNF-α production
by CD4+ and CD8+ T cells in response to antigen stimulation. Only
one animal immunized with EDIII+ AL had a consistent CD4+ T-
cell response, characterized by an increased frequency of CD4+
T cells producing IFN-γ or IFN-γ plus TNF-α upon stimulation with
EDIII and live DENV-2 (Supplementary Fig. 13). On the other hand,
three of four animals vaccinated with EDIII+ PP had such a CD4+
T-cell response. Overall, the antigen-speciﬁc CD4+ T-cell response
was signiﬁcantly superior in response to PP than AL adjuvants (Fig.
6d). A similar trend was observed for the CD8+ T-cell response,
even though the strongest responder was from the EDIII+ AL
vaccinated group (Fig. 6e and Supplementary Fig. 13d–f). Taken
together, these results show that the PP adjuvant combination
elicits more consistent nAb, CD4+ and CD8+ T-cell responses to
EDIII vaccination than AL, but that in our experimental setting
these levels of nAb and T-cell responses are still insufﬁcient to
protect against viral challenge.
DISCUSSION
In this study, we (1) determined immunological signatures that are
induced by ﬂavivirus infection using a PBMC model system, (2)
identiﬁed a TLR agonist combination that mimics the same
signatures, and (3) tested the ability of this combination to
stimulate nAb responses to a model dengue subunit vaccine and
protection against virus challenge in both mice and NHPs.
We developed a simple system to study the early immune
signatures to ﬂaviviruses in humans using infection of PBMCs
in vitro. The PBMC system showed a strong overlap with the gene
expression and cellular changes induced in the blood of human
subjects following YF-17D vaccination. The PBMC system made it
possible to study a panel of TLR agonists and ﬂaviviruses known to
induce nAbs in humans using a series of assays, including
upregulation of activation markers, cytokine secretion, and
transcriptional proﬁling. Our studies identiﬁed signaling through
IFNs, proinﬂammatory cytokines, TLRs, and acute phase response,
and DC maturation as common immune signatures induced by
ﬂavivirus infection. TLR agonists also induced most signatures but
no single TLR agonist was able to induce the full spectrum of
signatures.
Our integrated bioinformatic analysis of the phenotypic,
cytokine, and transcriptomic proﬁles from PBMCs and a cohort
of ﬂavivirus-naïve individuals immunized with YF-17D identiﬁed
immune signatures that are associated with nAb responses. The
combination of TLR2 agonist Pam3CSK4 and TLR3 agonist PolyI:C
(PP) best reproduced these signatures. Some identiﬁed signatures
were expected, such as DC activation and maturation and IFN
responses, others were unexpected, such as a positive association
with monocyte/Mφ-driven pro-inﬂammatory responses and Th1
cytokines, or a negative association of nAbs with B-cell responses.
Nonetheless, these results are consistent with previous reports
showing that the frequency of circulating PBs is associated with
total IgG, but not nAb titers in acute dengue patients.16,18 The
importance of a Th1 environment has also been suggested. In
mice, higher IFN-γ and IgG2b responses are associated with
induction of YF-17D nAbs.38 In humans, high frequency of virus-
speciﬁc CD4+ IFN-γ+ T cells at early time points is associated with
a strong nAb response to YF-17D vaccination.39 Levels of IFN-γ, IL-
12, and IFN-α are also found to be higher in dengue patients with
mild fever compared to those with more severe disease,40–42
indicating that a Th1 cytokine environment might also be related
to protection. Together, this suggests that induction of high nAb
titers after ﬂavivirus infection might depend on immune
mechanisms that differ from the classical model of B-cell
maturation and expansion leading to high antigen-speciﬁc IgG
titers.
Although monocytes/Mφ have received considerable attention
in ﬂavivirus infection due to their role in antibody-dependent
enhancement of infection, their role in driving immune responses
has not been thoroughly examined. We showed that in vitro,
human MΦs are likely the major cell type producing proinﬂam-
matory cytokines. MΦs were also critical in the generation of
immune responses after immunization with a PP-adjuvanted
formulation. In mice, depletion of macrophages by chlodronate
liposomes before EDIII+ PP immunization reduced nAb titers by
approximately tenfold. Furthermore, EDIII+ PP immunization
conferred partial protection in CD11c-Cre+/− IFNARﬂ/ﬂ mice, which
lack IFN-α receptor exclusively in CD11c+ DCs, but not in LysM-
Cre+/− IFNARﬂ/ﬂ mice, which lack IFN-α receptor in LysM+ MΦs.
This was consistent with previous reports of less effective
protective responses against DENV in the LysM-Cre+/− IFNARﬂ/ﬂ
model, and associated with lower IFN-γ levels.36 Differences in
immunostimulatory capacity of DCs and Mφs were also observed
after Leishmania infection, with Mφs being more effective than
DCs or B cells in eliciting Th1 responses.43
How could Mφs and a Th1 cytokine environment be more
conducive to nAb responses? It is possible that endogenous
cellular differences and/or modiﬁcation of the cellular environ-
ment by cytokines differentially affect antigen trafﬁcking, proces-
sing, and presentation. Differences in antigen-presenting cells
could also play a role, as subcapsular sinus Mφs are known to
present intact antigens to follicular B cells, whereas DCs generally
present processed antigens.17 It is also possible that the cellular
and cytokine environment induces differential antibody class
switching or glycosylation, inﬂuencing how efﬁciently the virus is
neutralized even through binding at the same epitope. Finally, the
Th1 environment could preserve better the diversity of Ab
response by limiting clonal selection and PB differentiation, which
might lead to the overproduction of a small number of highly
reactive, but poorly neutralizing Ab clones.
To determine whether reproducing ﬂavivirus immune signa-
tures with the PP adjuvant combination could be useful for DENV
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vaccine development, we tested the ability of PP to stimulate nAb
responses using the recombinant DENV-2 EDIII domain as a test
subunit antigen. For comparison, we used alum and TLR4 agonist
MPLA (AL), a standard adjuvant used in many vaccines. In mice,
signiﬁcantly higher level of nAbs and higher protection against
DENV-2 challenge were induced by EDIII+ PP immunization than
EDIII+ AL vaccination, in spite of a lower level of overall antigen-
speciﬁc IgG. In NHPs, EDIII+ PP but not EDIII+ AL consistently
induced both nAb and T-cell responses in all animals. These results
clearly show that mimicking immune signatures associated with
nAb responses with TLR agonists (PP) has the potential to
stimulate broader protective immune responses.
The levels of protection upon challenge, however, remained
intermediate. Compared to nonimmunized mice or NHPs, EDIII+
PP, but not EDIII+ AL, vaccination induced signiﬁcant protection
against DENV-2 challenge. However, no signiﬁcant difference in
protection was observed between EDIII+ PP and EDIII+ AL
vaccinations, raising concerns on the limitations of the current
studies, especially translation to humans. On one hand, the lack of
signiﬁcant difference in protection between EDIII+ PP and EDIII+
AL vaccinations could be due to the choice of AL as adjuvant
control, because after all AL is one of the widely used adjuvants for
vaccination in humans because of its potency. On the other hand,
the experimental methodology and design of the current studies
were not optimal to induce maximal immune responses so as to
confer better protection. In mice, the partial protection could be
due to the low dose of antigen (5 μg) and the two immunizations,
versus typically three or four injections of at least 50 μg of
antigens in most previous studies. In macaques, not all animals
reached the nAb threshold needed for protection (an apparent
>1:50 in our cynomolgus macaque DENV-2 infection model) and
only limited numbers of animals were used in each arm of the
experiment due to the cost and limited availability of the NHPs. In
humans, the correlation between nAb induction and speciﬁc
immune signatures in the current study was derived from a very
small number of YF-17D vaccinated individuals, which could have
overestimated the importance of the correlation. This could be
signiﬁcant considering that other immune signatures, besides the
strong monocyte/MΦ-driven responses and Th1 cytokine environ-
ment, were also correlated with nAb induction, although weakly.
In addition, EDIII does not contain important quaternary
neutralizing epitopes or potent T-cell epitopes that may be
needed for protective immunity in NHPs and humans. Despite
these caveats, the more consistent and broad nAb and CD4+ T-cell
responses induced by EDIII+ PP highlights the potential of
combining our approach with antigen optimization in dengue
and other vaccine development.
MATERIALS AND METHODS
Ethics statement
Research involving human PBMCs was approved by the Institutional
Review Board (NUS IRB 10-285). The YF-17D trial was previously
published.21 Trial approval was obtained from Singhealth Centralized
Institutional Review Board (ID:2013/385/E) and is registered under
clinicaltrials.gov registration no. NCT01943305. Animal experiments
performed at NUS (C57BL/6 mice), A*STAR (IFNAR mice) and SingHealth
(NHP) were approved by the respective Institutional Animal Care and Use
Committee and conducted following institutional guidelines.
Viruses and adjuvants
DENV-2 16681 (U87411.1), DENV-2 PDK53 (M84728.1), DENV-3 16562,
DENV-3 PGMK30FhL3,28 and YF-17D (X03700.1) were produced in Vero
(African green monkey) cells for the systems biology study. DENV-2 16681
and D2Y98P (JF327392.1) were produced in C6-36 (Aedes albopictus) cells
for challenge experiments. Adjuvants were obtained from Invivogen
(Vaccigrade) and used at the following concentration: Alhydrogel® 2%,
Pam3CSK4 2.5 μg/ml, PolyI:C 5 μg/ml, LPS 1 μg/ml, R848 2.5 μg/ml, and
ODN2006 5 μg/ml.
Systems biology study
PBMCs from four healthy, dengue-naïve donors (two male and two female
donors, aged 18–40 years old) were isolated by Ficoll density gradient. A
total of 107 cells per condition were treated with viruses at MOI= 1 and
adjuvants at the above concentrations. After 48 h, cells were used for
analysis by ﬂow cytometry and microarray and supernatant collected for
cytokine proﬁling.
Flow cytometry
PBMCs were diluted in FACS buffer (PBS, 0.5% BSA, 0.05% sodium azide) at
106 cells/100 μl and stained for 1 h at 4 °C with antibody cocktails as
described in Supplementary Table 2. Cells were washed twice and nuclei
counterstained with DAPI before acquisition on a BD LSRII cytometer.
Results were analyzed with FlowJo.
Microarray analysis
Total RNA was extracted from 106 PBMCs with Trizol (Ambion). cRNA
libraries were generated using the Illumina TotalPrep RNA Ampliﬁcation Kit
(Ambion) and hybridized to an Illumina HumanRef-12 V4 BeadChip
(Illumina) at 55 °C for 18 h, according to the manufacturer’s instructions.
After washing, blocking, and staining with streptavidin-Cy3, a high-
resolution Illumina Bead Array Reader confocal scanner (Illumina) was used
to scan the chip. Genome Studio (Illumina) was used to subtract
background from raw gene expression intensity data. Standard normal-
ization procedures for one-color array data and data analysis to identify
differentially expressed genes were performed using the GeneSpring GX
software, version 12.5 (Agilent Technologies). Signiﬁcantly regulated genes
(p < 0.05 with a cutoff of 1.5-fold change in treated compared to untreated
samples) were analyzed with IPA44 and GSEA.34
Cytokine proﬁling
Fluorescent bead measurement of cytokines, chemokines, and growth
factors in PBMC supernatents was performed using the Luminex
technology xMAP (Bioplex 27-plex human cytokine kit, Bio-Rad) as per
the manufacturer’s instructions. The standard curves were optimized
automatically by the software (Bioplex manager) and veriﬁed manually. In
order to prevent batch effect, samples were randomized prior to analysis.
Calibrations and validations were performed prior to analyses. In
experiments performed to validate the activity of combinations of
adjuvants, measurement of cytokine levels in human PBMC supernatants
(IL-12p40, IFN-γ) was done by ELISA (Biolegend) following the manufac-
turer’s recommendations.
WGCNA analysis
The recommended basic data processing and analysis procedure was
applied to our datasets.33 Data from 48 microarrays (mock, virus-infected,
and adjuvant-treated from four individual donors) expressed as log2 fold
change for each of 47,323 probes were processed by removing undetected
probes and selecting probes with the 70% highest variance. Sample
clustering detected no outliers. Module identiﬁcation was performed using
a signed network with power= 9, mergeCutHeight= 0.2, and minModu-
leSize= 30. Module eigengenes were correlated by Pearson correlation
with external traits. The following data were used as weights for external
traits: MFI of activation markers for immune cell activation and
concentration in pg/ml in the supernatant for cytokines. The genes in
relevant modules were analyzed by IPA and GSEA.
Infections of MDDCs and MDMΦs
Monocytes were isolated from PBMCs using the EasySepTM human
monocyte enrichment kit without CD16 depletion (StemCell) and
differentiated into MDDCs in the presence of 25 ng/ml GM-CSF+ 50 ng/
ml IL-4 (R&D Systems) or MDMΦs with 25 ng/ml M-CSF (R&D Systems) for
8–10 days. The phenotype of differentiated cells was conﬁrmed by ﬂow
cytometry using the panel of antibodies in Supplementary Table 3
(MDDCs: CD14- CD68- HLADR++ CD11c+ CD209/DC-SIGN+ and MDMΦs:
CD14+ CD68+ HLADR+ CD11c- CD209/DC-SIGN-) before infection with
DENV-2 16681 at MOI= 1 for 48 h.
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NF-κB and ISRE reporter cell lines
THP-1 and Jurkat-Dual reporter cell lines were purchased from Invivogen
and handled following the manufacturer’s recommendation.
DENV-2 EDIII expression
DENV-2 PDK53 residues 296–396 were used to express recombinant DENV-
2 EDIII. Brieﬂy, the EDIII sequence was ampliﬁed from cDNA obtained from
virus stocks using primers 5′ CACCAGTTACTCAATGTGTACCGGCAAG 3′ and
5′ CTATGACCCCTTCTTAAACCAGTTCAG 3′, then cloned in pET-TOPO-151
(Invitrogen) to add a N-terminal 6xHis tag and a TEV protease recognition
site. The plasmid was transformed in E.Coli BL21(DE3) and expression
induced with 0.25mM IPTG. After 16-h incubation at room temperature,
bacteria were lysed with BugBuster mastermix (Millipore) and centrifuged
at 11,000 g for 30 min. Pellet was resuspended in lysis buffer supplemented
with 8 M urea, bound to HisPur resin (ThermoFisher) and recombinant
protein eluted using a 50m M–1M gradient imidazole in wash buffer
(30mM sodium phosphate, 300mM NaCl, 10% glycerol, and 8 M urea).
Fractions containing EDIII as determined by SDS-PAGE and Coomasie blue
staining were dialized against storage buffer (30mM sodium phosphate,
300mM NaCl, and 10% glycerol). Folding was veriﬁed by ELISA using the
3H5 antibody (Millipore). For NHP immunizations, the 6xHis tag was
removed using the TEV protease (Invitrogen) following the manufacturer’s
recommendations.
Animal experiments
Mice. C57BL/6 mice were obtained from InVivos (Singapore). CD11c-Cre
IFNAR1ﬂ/ﬂ mice and LysM-Cre IFNAR1ﬂ/ﬂ36 were bred at Agency of Science,
Technology and Research (A*Star, Singapore). Mice (M/F, 7–10 weeks old)
were immunized s.c. with 106 PFUs DENV-2 16681, 5 μg DENV-2 EDIII+
20 μl Alhydrogel® 2%+ 10 μg MPLA (EDIII+ AL) or 5 μg DENV-2 EDIII+
10 μg Pam3CSK4+ 50 μg PolyI:C (EDIII+ PP) following the indicated
schedules. Challenge was performed by i.p. injection of 106 PFUs
D2Y98P. For depletion of MΦs, C57BL/6 mice were injected twice with
100 μl clodronate (CL-L) or control (PBS-L) liposomes (http://www.
clodronateliposomes.org), s.c. 7 days before and i.p. 3 days before
immunization. Innate immune responses to the adjuvanted vaccines were
analyzed in whole blood by ﬂow cytometry and quantitative real-time RT-
PCR, antibody responses by ELISA and PRNT, GC formation by immuno-
ﬂuorescence of spleen cryosections, and DENV-2 viremia after challenge by
quantitative real-time PCR and plaque assay as described below.
Nonhuman primates. Locally caught cynomolgus macaques (M/F, 3–5 kg)
were housed at the SingHealth Experimental Medicine Center. Animals
were immunized s.c. with 50 μg DENV-2 EDIII+ 200 μl Alhydrogel® 2%+
100 μg MPLA (EDIII+ AL) or 50 μg DENV-2 EDIII+ 100 μg Pam3CSK4+
500 μg PolyICLC (EDIII+ PP). PolyICLC was prepared as previously
described.37 Challenge was performed by s.c. injection of 106 PFUs
DENV-2 16681. The response to vaccination in NHP was followed during
7 days after the ﬁrst immunization. Rectal temperature was measured and
animals were observed daily for food and water intake, reaction at site, and
systemic adverse events. ALT and cytokine levels were measured in the
serum using an ALT enzymatic kit (Abcam) and the LegendPlex NHP
chemokine/cytokine 13-plex (Biolegend) following the manufacturer’s
recommendations. Innate immune responses to the adjuvanted vaccines
were analyzed in whole blood by ﬂow cytometry and quantitative real-
time RT-PCR antibody responses by ELISA and PRNT, DENV-2 viremia after
challenge by quantitative real-time PCR, and plaque assay and T-cell
responses by intracellular staining of antigen-stimulated splenocytes as
described below.
Analysis of cell activation by ﬂow cytometry in whole blood. Whole blood
was subjected to RBC lysis using ACK buffer. Cells were diluted in FACS
buffer (PBS, 0.5% BSA, 0.05% sodium azide) at 106 cells/100 μl and stained
for 1 h at 4 °C with antibody cocktails as described in Supplementary Table
4. Cells were washed twice and nuclei counterstained with DAPI before
acquisition on a BD LSRII cytometer. Results were analyzed with FlowJo.
Analysis of gene expression in whole blood. Whole blood was subjected to
RBC lysis using ACK buffer and cells lysed in RLT buffer (Qiagen).
Quantiﬁcation of host transcripts was performed by as previously
described.45 Results are expressed as the fold change normalized to
GAPDH and to untreated sample using the 2−ddCt method. The list of
primers used is shown in Supplementary Table 5.
ELISA. ELISA plates (Nunc) were coated with 2 μg/ml DENV-2 EDIII in PBS,
overnight at 4 °C. The next day, plates were washed once and blocked in
5% nonfat milk for 1 h, then incubated with serial dilutions of heat-
inactivated serum in 1% nonfat milk for 2 h at 37 °C. Depending on the
experiment, the following secondary antibody coupled to HRP were
incubated for 1 h at room temperature: goat polyclonal anti-mouse total
IgG (Biolegend), mouse anti-human/monkey IgG (clone G18-145, BD), goat
polyclonal anti-mouse IgM, IgG1, IgG2b, IgG3 (Abcam), or IgG2c (Pierce),
and mouse anti-human/monkey IgG1 (clone HP6069, Thermo). TMB
substrate was added for 5 min and reactions stopped with 2 N H2SO4.
OD450 values were ﬁtted with a nonlinear regression with variable slope
(four parameters) in GraphPad Prism and antibody titers were deﬁned as
the lowest dilution with signal two times above background. Statistical
differences are evaluated based on the log10 antibody titers.
PRNT. Plaque reduction neutralization assay was performed as previously
described.21 Brieﬂy, BHK-21 cells were maintained in RPMI+ 10% FBS and
seeded in 24-well plates for the assay. Serial dilutions of heat-inactivated
serum were pre incubated with 50 PFUs of DENV-2 16681 for 2 h at 37 °C
before allowing infection of the cell monolayer for 1 h. Cells were
overlayed with maintenance media supplemented with 1% CMC and
plaques stained 5 days later with 1% crystal violet. Curves were ﬁtted in
GraphPad Prism using a four parameter logistic regression and the PRNT50
calculated as the serum concentration leading to a 50% reduction in
plaques from the virus only control. Statistical differences are evaluated
based on the log10 PRNT50.
Quantiﬁcation of DENV-2 viremia. The quantiﬁcation of DENV-2 viral load
in the serum of challenged animals was performed following standard
protocols previously published. Brieﬂy, plaque assay was performed by
infecting monolayers of BHK-21 cells with serial dilutions of serum,
overlaying with maintenance media supplemented with 1% CMC, and
staining plaques 5 days later with 1% crystal violet. Quantitative real-time
RT-PCR was performed following the CDC assay.46 For both methods, the
area under the curve and the peak value of titer for the ﬁrst 7 days after
challenge were calculated using GraphPad Prism.
Immunoﬂuorescence of mouse spleen cryosections. Mouse spleens were
collected at 7 days post immunization, embedded in OCT medium and
frozen at −80 °C before processing into 5 μm sections. Samples were ﬁxed
in cold 4% paraformaldehyde for 10min followed by blocking in 5% FBS
for 1 h at room temperature. For GC analysis, Alexa-Fluor 594 B220
(Biolegend 103254), Alexa-Fluor 488 anti-mouse IgG (Biolegend 405319),
and Alexa-Fluor 647 anti-GL-7 (Biolegend 144605) or for macrophage
depletion, Alexa-Fluor 594 B220, FITC anti-mouse CD68 (Biolegend 137005)
/FITC anti-mouse CD11c (Biolegend 117305), and Alexa-Fluor 647 anti-
mouse CD169 (Biolegend 142407) were incubated at 1:100 overnight at 4 °C.
Samples were mounted on glass slides in ProLong Antifade reagent
(Invitrogen). Images were acquired on a Zeiss LSM700 confocal microscope
and on a Mirax Midi slide scanner system for whole organ imaging. GCs
were deﬁned as discrete areas of B220, GL-7, and IgG signal colocalization
and counted manually in each spleen section. PBs were deﬁned as IgG+
cells and quantiﬁed in two 1mm2 areas in each spleen section using
ImageJ.
T-cell intracellular staining of NHP splenocytes. Splenocytes from NHPs
were processed on ice immediately after killing. A total of 106 cells per
condition were left unstimulated or restimulated for 16 h with 10 μg/ml
EDIII, 107 PFUs DENV-2 16681, or 20 ng/ml PMA+ 1ug/ml ionomycin as a
positive control. Brefeldin A and monensin (Biolegend) were added at
1:2000 each for the last 5 h of stimulation. Cells were incubated with Near
IR Live/Dead stain (Thermo), ﬁxed with Cytoperm/Cytoﬁx (BD), and then
stained with CD3, CD4, CD8, IFN-γ, and TNF-α antibodies as described in
Supplementary Table 6. Cells were acquired on the Attune NxT ﬂow
cytometer (Thermo) and results analyzed with FlowJo. The T-cell response
was considered signiﬁcant if the frequency of responding cells was greater
than threefold that of the average of unstimulated cells.
Statistical analysis
The method used for statistical analysis is indicated in each ﬁgure legend.
More detailed description of the statistical methods used in microarray and
WGCNA analysis are available in the respective methods section.
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Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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